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Abstract: Purpose To assess the impact of Jordanian’s Corona Virus Disease (COVID-19) lockdown
on visual acuity and macular thickness in patients with macular edema receiving intravitreal injections,
and to assess the ethical endeavor of lockdown among serious sight threatening conditions. Patients
and Methods This retrospective observational study included patients planned for intravitreal injections
who did not complete the planned course before the lockdown (ie, before 20th of March 2020). Data
included demographics, indication for the intravitreal injection, corrected distance visual acuity (CDVA),
and central macular thickness on Optical Coherence Tomography (OCT) before and after the lockdown.
Results One-hundred and sixty-six eyes of 125 patients were studied, 68 (54.4%) patients were males, and
the mean (± standard deviation, SD) age was 64.79 (±9.41) years. Mean (±SD) duration of delay in
the planned injection was 60.97 (±24.35) days. The change in visual acuity was statistically significant
for patients with diabetic macular edema (p= 0.045 improvement), patients with central retinal vein
thrombosis (CRVO) (p= 0.05 deterioration), and patients with age-related macular degeneration (AMD)
(p= 0.005 deterioration). Of interest, delay of more than 2 months and the previous need for 3 or more
injections were significant poor prognostic factors for visual outcome for patients with diabetic macular
edema (p=0.027 and 0.045). Conclusion The impact of delay in the scheduled intravitreal injections
resulted in variable outcomes depending on the indication. Triaging the urgency of patients should be
based on the indication to support the equity principle of bioethics, where those in need are prioritized
against others, depending on potential adverse outcome.
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Purpose: To assess the impact of Jordanian’s Corona Virus Disease (COVID-19) lockdown 
on visual acuity and macular thickness in patients with macular edema receiving intravitreal 
injections, and to assess the ethical endeavor of lockdown among serious sight threatening 
conditions.
Patients and Methods: This retrospective observational study included patients planned 
for intravitreal injections who did not complete the planned course before the lockdown (ie, 
before 20th of March 2020). Data included demographics, indication for the intravitreal 
injection, corrected distance visual acuity (CDVA), and central macular thickness on Optical 
Coherence Tomography (OCT) before and after the lockdown.
Results: One-hundred and sixty-six eyes of 125 patients were studied, 68 (54.4%) patients 
were males, and the mean (± standard deviation, SD) age was 64.79 (±9.41) years. Mean 
(±SD) duration of delay in the planned injection was 60.97 (±24.35) days. The change in 
visual acuity was statistically significant for patients with diabetic macular edema (p= 0.045 
improvement), patients with central retinal vein thrombosis (CRVO) (p= 0.05 deterioration), 
and patients with age-related macular degeneration (AMD) (p= 0.005 deterioration). Of 
interest, delay of more than 2 months and the previous need for 3 or more injections were 
significant poor prognostic factors for visual outcome for patients with diabetic macular 
edema (p=0.027 and 0.045).
Conclusion: The impact of delay in the scheduled intravitreal injections resulted in variable 
outcomes depending on the indication. Triaging the urgency of patients should be based on 
the indication to support the equity principle of bioethics, where those in need are prioritized 
against others, depending on potential adverse outcome.
Keywords: COVID-19 lockdown, COVID-19 pandemic, ethics, intravitreal injection, 
macular edema
Introduction
The recently emerged viral outbreak of the Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2) led to the Corona Virus Disease (COVID-19) 
Pandemic. This disease was announced as a global pandemic by the World 
Health Organization on 11th of March 2020.1 The pandemic led to several nation- 
wide lockdown decisions throughout the world, accompanied by healthcare bodies’ 
guidelines on how to deal with patients during the pandemic.2 Ophthalmology is 
among the fields where physicians have close contact with patients during exam-
ination, and considering the possibility of COVID-19 manifesting as conjunctivitis, 
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ophthalmologists might be the first to contact a COVID-19 
patient, and several measures are now suggested to protect 
against infection.2–5
Intravitreal injection is the most commonly performed 
ophthalmic procedure, with the number of injections given 
yearly having increased 100-folds during the last decade, 
as patients with different indications are given a significant 
number of injections yearly.6–9 In March 2020, the 
American Academy of Ophthalmology (AAO) issued 
a recommended practice guideline urging practicing 
ophthalmologists to provide care for only “urgent” or 
“emergent” cases.10 The Academy recognized that 
“urgency” is determined by physician’s own judgment, 
taking into account individual patient medical and social 
circumstances. While the AAO recommendation left the 
decision of determining urgency or emergency to the treat-
ing physicians, the American Society of Retina Specialists 
described intravitreal injection therapy as “essential”.11
In Jordan, the first SARS-CoV-2 infected case was 
registered on the 2nd of March 2020 for a Jordanian 
citizen coming from Italy.12 On 18 March 2020, 
a nationwide lockdown was announced restricting all 
movements, including healthcare institutions, with an 
exemption for emergency departments. The lockdown 
decision led to a reduction in transport mobility of up to 
95% compared to baseline, where hospital visits were 
carried out only by ambulances.13 These restrictions led 
to cessation of intravitreal injection administration in 
Jordan, until 28th of April, where these injections 
resumed. The decision to discontinue intravitreal injection 
during the current COVID-19 pandemic in Jordan repre-
sented part of a more general decision to suspend all 
elective and semi-urgent procedures in order to achieve 
better allocation of the potentially scarce medical 
resources in this developing country to those who need it 
the most.14 However, the clinical impact of such decision 
and its ethical implications were not fully considered.
In this study, we aim to assess the impact of Jordan’s 
lockdown on visual acuity and macular thickness in 
patients receiving intravitreal injection, and their percep-
tion about their change in vision during the lockdown 
period. We will then discuss briefly the ethical considera-
tion of the principle of justice, in particular equity versus 
equality, in this particular setting.
Patients and Methods
This was a retrospective observational study that took 
place at Jordan University Hospital from 20th of April to 
1st of July, 2020. The Ophthalmology Department is 
a tertiary referral center for the management of ocular 
diseases. This study was conducted in accordance with 
the Declaration of Helsinki. Ethical approval was granted 
by the Institutional Review Board (IRB) at Jordan 
University Hospital, and all patients signed an informed 
consent prior to participating in the study.
The study included 125 patients who were planned for 
intravitreal injections for different indications, but were 
unable to complete the planned intravitreal injections 
before the lockdown (ie, before 20th of March 2020). At 
our institution, we adopt a pro re nata (PRN) approach for 
treating patients with intravitreal injections, where 
a loading dose of three intravitreal injections is given 
followed by a monthly follow-up visit. Patients were 
invited to attend when intravitreal injections resumed. 
Indications included diabetic macular edema, proliferative 
diabetic retinopathy (PDR), neovascularization in age- 
related macular degeneration (AMD), branch retinal vein 
occlusion (BRVO), and central retinal vein occlusion 
(CRVO). Exclusion criteria included patients who refused 
to participate, and inability to access patients’ previous 
records, mainly due to patients’ attending another institu-
tion for treatment. For patients who received bilateral 
injections, an injection was given in the more severely 
affected eye, and then the other eye received an injection 
one week later. Although we included both eyes, we 
interviewed the patient and asked about each eye 
separately.
When the Department resumed its work, several pro-
tective measures were implemented to protect against the 
infection when intravitreal injections were restarted. These 
included:
-A phone call to take a brief history about any symp-
toms or contact with COVID-19positive individuals.
-Upon confirming a no contact history and absence of 
any COVID-19 related symptoms, the patient was invited 
for the injection, where a temperature check using a non- 
contact device before admission to the building was 
performed;
-Providing two separate theaters in two separate build-
ings supervised by two separate teams, to prevent over-
crowding and allow distancing between patients;
-Limiting the number of injections to 15 during a 4 
hours period, where each patient will attend at an allocated 
time slot to facilitate distancing;
-The patients and ophthalmology team members wore 
protective surgical masks, noting that the patient’s mask 
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moved down the nose during cleaning with povidone, 
draping, and injection administration.
When a patient visits the hospital to resume his/her 
intravitreal injections, an ophthalmology resident first 
explains the nature of the study and obtains the informed 
consent. Data regarding the corrected distance visual 
acuity (CDVA), slit lamp examination and central macular 
thickness on Optical Domain Tomography (OCT) before 
the lockdown were obtained from the electronic medical 
records (EMR), including hemoglobin A1c within one 
month of inclusion. Then, a questionnaire was carried 
out asking about demographic variables, co-morbidities, 
patients’ anxiety and perception regarding their visual 
acuity change during lockdown, and their trust in the 
treating physician and in the recent medical institutional 
decisions and actions during lockdown. The questions 
about anxiety and trust are straight forward questions 
with the answer being a scale from 0 (least) to 10 
(most). After the questionnaire, the CDVA, measured 
using a Snellen chart at 6m, was recorded using the dec-
imal system, then slit lamp and fundus examination was 
performed. Finally, a new macular thickness OCT was 
obtained. OCT images before and after the lockdown 
were obtained using RTVue-100 Fourier-Domain high- 
resolution Optical Coherence Tomography (OCT) from 
Optovue, Inc., Fremont, CA.
For sub-group analysis, we categorized patients con-
cerning number of previous injections into those who did 
not yet complete a loading dose (ie, less than 3 injections), 
and those who took three or more injections before the last 
treatment plan was decided upon. We also categorized the 
delay in injection into less and equal to two months and 
more than two months. For patients with visual acuity less 
than 0.05 on the decimal system, we measured visual 
acuity via counting fingers, hand motion, light perception, 
and no light perception, which were then converted into 
0.014, 0.005, 0.0016, and 0.0013, respectively.15
Statistical Analysis
IBM SPSS Statistics for Windows, version 21 (IBM Corp., 
Armonk, N.Y., USA) was used in our analysis. The mean 
(± standard deviation, SD) was used to describe continu-
ous variables (eg, age) and count (frequency) to describe 
other nominal variables (eg, gender). Paired sample t-test 
was used to analyze the change in visual acuity and in 
macular thickness before and after the lockdown period. 
After calculating the difference in visual acuity and macu-
lar thickness before and after the lockdown period, 
Pearson correlation test was performed to analyze the 
correlation with duration of delay in the planned injec-
tions, and with responses of the questionnaire. One-way 
ANOVA was used to analyze the difference in visual 
acuity change or macular thickness changes with the indi-
cation of injections. A cut-off value of p ≤ 0.05 was 
considered statistically significant.
Results
One hundred and twenty-five patients were included in this 
study, with a mean (±SD) age of 64.79 (±9.41) years, 
ranging from 35 to 91 years. Sixty-eight (54.4%) males 
and fifty-seven (45.6%) females were included. One hun-
dred and two patients (81.6%) had diabetes mellitus with 
a mean (±SD) hemoglobin A1c (HbA1c) of 7.65 (± 1.34), 
71 (56.8%) had hypertension, and 31 (24.8%) had 
ischemic heart disease.
There were 166 eyes, 82 (49.4%) were bilateral eyes 
from 41 patients. Eighty-six (51.8%) were right eyes, and 
80 (48.2%) were left eyes. The mean (±SD) duration of 
delay in the planned injection was 60.97 (± 24.35) days 
(range 29 to 210 days). Table 1 shows the demographic 
features and the characteristics of the included sample.
Upon analyzing the change in visual acuity and macu-
lar thickness, there was improvement in visual acuity for 
patients with diabetic macular edema and patients with 
proliferative diabetic retinopathy (PDR), and deterioration 
in visual acuity for patients with age-related macular 
degeneration (AMD), branch retinal vein occlusion 
(BRVO), and central retinal vein occlusion (CRVO). In 
addition, there was improvement (decrease) in macular 
edema for all patients except those with CRVO (Table 
2). The change in visual acuity was statistically significant 
for patients with macular edema (p=0.045, improvement), 
patients with CRVO (p= 0.05, deterioration), and patients 
with AMD (p= 0.005, deterioration). No statistically sig-
nificant difference in macular thickness was noticed for all 
indications (p= 0.128). No statistically significant correla-
tion was found between change in visual acuity or macular 
thickness and duration of delay (p=0.09 and 0.817, respec-
tively), gender (p=0.720 and 0.312, respectively), or other 
co-morbidities. According to changes in visual acuity with 
delay in intravitreal injection, we developed a framework 
to prioritize patients scheduled for intravitreal injections 
according to the indication, where patients with the highest 
expected chance of worsening are prioritized.
We performed a sub-group analysis for DME patients 
(n= 109) to analyze the effect of the duration of delay and 
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the number of previous injections on the change in CDVA 
and OCT macular thickness (Table 3). Patients who had 
a delay of more than 2 months had significantly worse 
visual acuity compared to those with less than 2 months 
delay (p= 0.027, mean difference 0.070, 95% CI 0.008–-
0.13), and they had less improvement in macular thickness 
(p=0.047). Moreover, patients who had previously 
received 3 or more injections had significantly worse 
visual acuity compared to those who took less than 3 
injections (p= 0.045, mean difference 0.068, 95% CI 
0.002–0.13).
Upon analyzing the overall change in macular edema, 
irrespective to indication, we found a significant change in 
macular thickness that occurred during the delay (p= 
0.041); with the mean (±SD) macular thickness before 
commencement of injection being 401.70 μm (±146.64) 
compared to 369.09μm (±156.14), with a mean difference 
of 32.62μm (95% CI 1.35–63.89). No significant differ-
ence was observed in overall changes in visual acuity (p= 
0.294), as the mean difference was 0.014 (95% CI 
0.04–0.012).
As for complications suffered by patients enrolled in 
this study, four patients had an incidence of vitreous 
hemorrhage, and two patients had neovascularization of 
the iris.
Table 4 shows the answers on the subjective assess-
ment. The majority of patients rated their vision from very 
poor to fair 128 (77.1%). There was a significant positive 
correlation between patient’s reported worsening of vision 
and duration of delay (p= 0.001, Pearson coefficient= 
0.258), although no significant correlation was found 
between patients’ reported worsening of vision and the 
objectively measured change in visual acuity (p= 0.078).
Discussion
In our analysis of the outcomes of delayed intravitreal 
injection during COVID-19 lockdown, we observed vari-
able outcomes according to the indication of injection, 
where the change in visual acuity was statistically signifi-
cant for patients with macular edema (p=0.045, improve-
ment), patients with CRVO (p= 0.05, deterioration), and 
patients with AMD (p= 0.005, deterioration). Since the 
beginning of the COVID-19 pandemic, several ophthal-
mologists published their experiences and proposed stra-
tegies in dealing with patients in need for intravitreal 
injections during the pandemic.10,11,16–18 Almost all con-
cur that the number of injections given to a patient during 
the pandemic is less than intended.19 Furthermore, 
Romano et al showed that the COVID-19 related lock-
down in Italy led to a delay in delivery of intravitreal 
injections to neovascular age-related macular degeneration 
Table 1 Characteristics of the Included Sample
Count % Mean (± 
Standard 
Deviation)
Laterality Right 86 51.8%
Left 80 48.2%




































Visual acuity before 0.30 (± 
0.24)
Visual acuity after 0.32 
(±0.26)
Macular thickness (µm) before 398.31 
(±138.21)
Macular thickness (µm) after 370.04 
(±150.33)
Abbreviations: AMD, age-related macular degeneration; DME, diabetic macular 
edema; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; 
PDR, proliferative diabetic retinopathy.
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patients, which led to higher frequency of complications in 
this patient group compared to before lockdown.20 In this 
study, most of the patients had diabetic macular edema. 
The impact of delayed injection was highly variable 
depending on multiple factors including indication for 
injection, delay to get injection, number of injections 
received before the study, and other factors. Patients with 
CRVO, patients with AMD, and patients with diabetic 
macular edema that mandated three or more injections 
had a significant deterioration in visual acuity and macular 
edema after the delayed injection. Despite the need for 
further studies, we suggest that ophthalmologists should 
not postpone the provision of intravitreal injection services 
for this group of patients for more than 2 months even 
amid the COVID-19 lockdown and should treat this parti-
cular group of patients as emergency cases in order to 
Table 2 Comparison Between Different Indications in Regard to Visual Acuity and Macular Thickness Change (After – Before) During 
the Delay Caused by COVID-19 Lockdown
N Visual Acuity Difference Macular Thickness Difference (µm)
Mean Std. Deviation Mean Std. Deviation
Diagnosis AMD 22 −0.04 0.12 −13.29 195.98
DME 109 0.02 0.18 −50.91 132.80
BRVO 10 −0.03 0.17 −22.67 282.30
CRVO 4 −0.09 0.14 217.00 174.94
PDR 19 0.11 0.18 −37.06 131.74
Other 2 −0.10 0.14 −115.00 –
Total 166 0.01 0.17 −32.62 161.58
Abbreviations: AMD, age-related macular degeneration; DME, diabetic macular edema; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; PDR, 
proliferative diabetic retinopathy.
Table 3 Subgroup Analysis for Diabetic Macular Edema Patients to Analyze the Effect of the Duration of Delay and the Number of 
Previous Injections on the Change in VA and OCT Macular Thickness
Change in VA Change in Macular Thickness (µm)
Mean Standard Deviation p value Mean Standard Deviation p value
Previous injections <3 0.05 0.16 0.045 −56.52 107.70 0.734
3 and more −.02 0.19 −44.48 158.73
Duration of delay 1–2 months 0.06 0.15 0.027 −66.08 147.24 0.0472
>2 months −.01 0.16 −40.23 122.44
Abbreviation: VA, visual acuity.
Table 4 Answers of the Patient-Reported Questionnaire
Count % Median Minimum Maximum




Very poor 8 4.8%
Blind 0 0.0%
Worsening of vision during lockdown 1.00 0.00 10.00
Anxiety due to lockdown delay in injections 3.00 0.00 10.00
Healthcare trust 8.00 1.00 10.00
Clinical Ophthalmology 2021:15                                                                                             submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                         
665
Dovepress                                                                                                                                                           Elfalah et al
avoid deterioration in visual acuity. Moreover, it appears 
that less than 2 months delay in injection can be well 
tolerated and compensated for. Ethically, triaging the 
urgency of patients should be based on the indication to 
support the equity against equality, where those in need are 
prioritized against others, depending on the urgency and 
potential adverse outcomes.21
Several authors have discussed the ethical impact of the 
pandemic on delivering treatments to patients in need since 
the beginning of the COVID-19 outbreak.22,23 Concerns 
regarding delivering care to cancer patients were the most 
commonly addressed.24 Cancer patients are usually immuno-
compromised and at higher risk of adverse outcomes asso-
ciated with COVID-19 infection.25 In addition, the disruption 
of the treatment plan that is usually decided on at the inception 
of the diagnosis might result in progression, recurrence and 
up-staging. These concerns led to the adoption of a framework 
to prioritize treatment delivery for cases; priority should be 
based on the probability of mortality and morbidity; high 
mortality and morbidity due to treatment delay should be 
given priority over those with a lower probability of morbidity 
and mortality where delay will not affect the outcome.25 
A similar framework can be adopted for patients receiving 
intravitreal injections suffering from sight threatening condi-
tions, especially when the available resources are limited 
precluding the accommodation of all patients (Figure 1).
Over the last few months, the clinical impact of delay-
ing intravitreal injections in patients with neovascular 
AMD was the most widely studied. A UK study to esti-
mate the reduction in neovascular AMD referral and the 
corresponding increase in poor vision if there was 
a 3-months delay in treatment showed a 72% reduction 
in neovascular AMD referrals which might result in an 
increase in the percentage of patients developing visual 
acuity <6/60 from 15.5% to 23.3%.26 In our sub-group 
analysis; AMD, CRVO, and BRVO patients had worsened 
due to the delay in injections. Our results are supported by 
the EXCITE study, where a delay in monthly injections led 
to poorer outcomes.27 In a study comparing the risk of 
COVID-19 infection and transmission among neovascular 
AMD patients with visual impairment caused by the neo-
vascular AMD, Boyd et al reported that reduced disease 
burden from avoiding visual impairment outweighs the 
expected health-adjusted life-years lost from COVID-19 
transmission.28 For CRVO, the long-term follow-up in the 
HORIZON trial previously showed that a delay in follow- 
up resulted in worsening of the visual acuity in CRVO but 
not in BRVO patients, in concordance with our sub-group 
analysis.29 As diabetic macular edema represents the most 
common indication for intravitreal injection in our cohort, 
and the most common cause of vision loss from diabetic 
retinopathy,30 we further sub-analyzed diabetic macular 
edema patients. We reported a worsened outcome in 
patients who had two or more months delay and received 
three or more injections compared to those with less than 
two months delay or those who received less than three 
injections. These findings are consistent with studies 
showing variability in response to anti-VEGF therapy 
among diabetic patients, where the first few anti-VEGF 
doses are the most effective.31 An interesting finding is 
that despite the subjective feeling reported by patients in 
regard to worsened CDVA during the lockdown period, the 
overall CDVA measured objectively was not significantly 
different (p= 0.294).
Our study suggests a link to an important ethical con-
cept; justice and the fairness of allocating limited medical 
services. Justice, along with autonomy, beneficence, and 
non-maleficence are the four pillars of an ethical endeavor 
to patients during clinical care.32 These principles are 
encountered in the daily practice of physicians and other 
healthcare providers.33 Justice is defined as providing 
a healthcare system that is compatible with the law and 
rights of the individual, but also is fair and balanced from 
a societal perspective (the medical portal; Medical Ethics 
explained: justice). Finding the balance between individual 
and societal benefits can be troublesome, particularly amid 
emergencies like the COVID-19 pandemic. In our exam-
ple, patients should be subdivided, scientifically, into those 
at high risk of vision deterioration if injections were not 
administered on time, and those at low risk of vision 
Figure 1 A framework for prioritizing patients receiving intravitreal injections 
based on their indications. 
Abbreviations: AMD, age-related macular degeneration; DME, diabetic macular 
edema; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; 
PDR, proliferative diabetic retinopathy.
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deterioration with delay. In this particular example, delay-
ing the injection has resulted in an inferior outcome to 
CRVO and neovascular AMD and variable outcomes in 
diabetic patients. However, the delay in injections prob-
ably did provide benefit in the form of reduction of disease 
transmission to society due to the imposed lockdown.
Sight is considered one of the five senses, which when 
compromised might negatively affect the quality of life of 
individuals. Similar to prioritizing treatment to cancer 
patients during total lockdowns, practicing evidence- 
based medicine would help deliver care to those who 
need it the most and allows for ethical prioritization and 
allocation of resources.34 We could argue that, based on 
our findings, CRVO, neovascular AMD, and patients with 
diabetic macular edema who required more than three 
injections should be prioritized when planning the delivery 
of intravitreal injections during total lockdowns. By tailor-
ing the treatment to those in most need, equity can be 
considered the ethical value that support the decision- 
making by the treating physician.
Diabetic retinopathy is one of the most common causes 
of blindness worldwide.30 Poorly controlled diabetes 
remains the major contributor of diabetic retinopathy pro-
gression. Patients with uncontrolled diabetes are also more 
susceptible to infections, including viruses.35 This imposes 
a dilemma, where protecting patients against infections by 
delaying their appointments might lead to a delay in dia-
betic retinopathy treatment. While several reports,19 
including ours, showed that delivering treatment in well- 
controlled conditions will not lead to infection contraction, 
this should be further studied in the future. Policy makers 
should bear into account the vision-related morbidities 
related to any delay in intravitreal injections, particularly 
for CRVO and neovascular AMD, and their treatment 
should be continued under well-controlled conditions to 
also prevent any spread of infection.
The main limitation in our study was the short follow- 
up period, where the long-term impact of the lockdown on 
patients’ visual outcomes is yet to be unraveled. Moreover, 
the small number of patients in each subgroup may hinder 
the generalizability of our sub-group analysis. The small 
number also did not allow us to analyze the difference 
between each type of injection and the outcome.
While retina and its diseases are the major topics where 
high-quality evidence and randomized controlled trials 
present,36 we believe our study can help policymakers in 
the decision making, patient prioritization and allocation 
of resources during times of crises and lockdowns and, in 
this particular example, how to prioritize patients who 
should be receiving intravitreal injections.
Conclusion
The present study was conducted on a small Jordanian 
cohort of patients with various eye conditions requiring 
intravitreal injections, who encountered a delay due to the 
recent COVID-19 pandemic lockdown in Jordan. The 
delay in the scheduled intravitreal injections resulted in 
negative variable outcomes depending on the indication of 
injection. We recommend that triaging the urgency of 
patients based on the indication of intravitreal injection 
might be a safe approach in potential future lockdowns 
and emergencies. Priority should be given to patients who 
are expected to deteriorate due to any delay. In diabetic 
patients receiving intravitreal injections, a delay of more 
than 2 months should be avoided. In this particular setting, 
equity and not equality should refurbish.
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